MRC1 and cancer: Because triterpenoids have a cancer cell mutation-agnostic decrease in macrophage CD206 and increased lymphoid activation, this strengthens support for their potential clinical utility and would indicate KEAP1-mutant treatment-resistant cancers may still benefit from triterpenoid therapy.